Lupin, INC.
Manufacturer of generic pharmaceuticals, biosimilars, and branded pharmaceuticals.
Based in MD
AI Overview
With $750K in lobbying spend across 16 quarterly filings, Lupin, INC is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2021 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $100K |
| 2022 | $200K |
| 2023 | $200K |
| 2024 | $200K |
| 2025 | $50K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Lupin, INC. disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Defense
Advocacy for U.S. production of key pharmaceuticals necessary to support the U.S. supply chain related to pandemic preparedness and prevention
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.